Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTYQANR)

DTT Name	Cerebroside-sulfatase (ARSA)
Synonyms	Cerebrosidesulfatase; Arylsulfatase A component C; ASA; ARSA
Gene Name	ARSA
DTT Type	Successful target	[1]
BioChemical Class	Sulfuric ester hydrolase
UniProt ID	ARSA_HUMAN
TTD ID	T98157
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
EC Number	EC 3.1.6.8
Sequence	MGAPRSLLLALAAGLAVARPPNIVLIFADDLGYGDLGCYGHPSSTTPNLDQLAAGGLRFT DFYVPVSLCTPSRAALLTGRLPVRMGMYPGVLVPSSRGGLPLEEVTVAEVLAARGYLTGM AGKWHLGVGPEGAFLPPHQGFHRFLGIPYSHDQGPCQNLTCFPPATPCDGGCDQGLVPIP LLANLSVEAQPPWLPGLEARYMAFAHDLMADAQRQDRPFFLYYASHHTHYPQFSGQSFAE RSGRGPFGDSLMELDAAVGTLMTAIGDLGLLEETLVIFTADNGPETMRMSRGGCSGLLRC GKGTTYEGGVREPALAFWPGHIAPGVTHELASSLDLLPTLAALAGAPLPNVTLDGFDLSP LLLGTGKSPRQSLFFYPSYPDEVRGVFAVRTGKYKAHFFTQGSAHSDTTADPACHASSSL TAHEPPLLYDLSKDPGENYNLLGGVAGATPEVLQALKQLQLLKAQLDAAVTFGPSQVARG EDPALQICCHPGCTPRPACCHCPDPHA
Function	Hydrolyzes cerebroside sulfate.
KEGG Pathway	Sphingolipid metabolism (hsa00600 ) Lysosome (hsa04142 )
Reactome Pathway	Glycosphingolipid metabolism (R-HSA-1660662 )
BioCyc Pathway	MetaCyc:HS02032-MON

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
OTL-200	DMQNI7O	Metachromatic leukodystrophy	5C56.02	Approved	[2]
------------------------------------------------------------------------------------

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HGT-1111	DMDZE3B	Metachromatic leukodystrophy	5C56.02	Phase 2	[1]
------------------------------------------------------------------------------------

The Drug-Metabolizing Enzyme (DME) Role of This DTT

DTT DME Name

Arylsulfatase A (ARSA) DME Info

Gene Name

ARSA

1 Approved Drug(s) Metabolized by This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Micafungin	DM6Y3AN	Aspergillosis	1F20	Approved	[3]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00681811) Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Orchard Therapeutics.
3	The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66.